11 Jan 2019 Research

Myelofibrosis: Finding new ways to treat patients

Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.

Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.

Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.

The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.

Related posts

Leukaemia UK announces John Goldman Fellows for 2022

8 November 2022

Leukaemia UK announces John Goldman Fellows for 2022

Leukaemia UK has awarded their prestigious John Goldman Fellow research grants to four outstanding early-career researchers seeking to advance our understanding of and ability to treat blood cancer. Leukaemia UK…

Nurse who made throwaway comment before blood cancer diagnosis welcomes new research boost into ‘Natural Killer’ cells

29 February 2024

Nurse who made throwaway comment before blood cancer diagnosis welcomes new research boost into ‘Natural Killer’ cells

A former nurse, midwife, health visitor and NHS manager is welcoming new research into her particular blood cancer, after not recognising her mystery symptoms were leukaemia.  Kay Cutting, from Seaham…

Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl

25 November 2025

Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl

Today, NICE announced its recommendation for Aucatzyl (obecabtagene autoleucel), a CAR-T therapy, to be made available on the NHS for treating adults aged 26 and over with relapsed or refractory…

Non-existent awareness of leukaemia symptoms “extremely worrying” – say leading UK leukaemia charities, as they launch memorable new campaign to get people “parroting on” about the symptoms

24 August 2022

Non-existent awareness of leukaemia symptoms “extremely worrying” – say leading UK leukaemia charities, as they launch memorable new campaign to get people “parroting on” about the symptoms

People over 55 also underestimate their risk, thinking that leukaemia is a childhood disease. Only 11% of over 55s thought that they had the greatest risk of leukaemia[1], whereas in…